ArticleRetina (Philadelphia, Pa.)2024
RB1 CIRCULATING TUMOR DNA IN THE BLOOD OF PATIENTS WITH RETINOBLASTOMA INCREASES IN UNTREATED PATIENTS.
Article in Retina (Philadelphia, Pa.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blood-Based Cell-Free DNA in Ophthalmic Oncology.Translational vision science & technology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeCirculating tumor DNA (ctDNA) in plasma has been identified in many cancers, including retinoblastoma at diagnosis. It has previously been shown that with treatment (enucleation or ophthalmic artery chemosurgery), all ctDNA disappears; if there is persistent plasma ctDNA after treatment, metastases develop. The purpose of this study was to determine how the ctDNA RB1 variant allele frequency changes in patients with retinoblastoma who have delayed treatment.
methodsCirculating tumor DNA RB1 was detected, and variant allele frequency was measured at diagnosis and again before any intervention at some time later ranging from 2 days to 28 days.
resultsFour patients with five ctDNA RB1 mutations were detected at diagnosis, and variant allele frequency was increased on reevaluation of the same RB1 mutations in ctDNA.
conclusionIn this small cohort, every patient (4) and every RB1 mutation (5) plasma level VAF% increased when measured at two time periods before treatment was initiated suggesting that growing tumors demonstrate increasing plasma ctDNA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.